{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:44:24Z","timestamp":1759495464217,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00277-017-3226-0","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T08:39:46Z","timestamp":1515573586000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Program death inhibitors in classical Hodgkin\u2019s lymphoma: a comprehensive review"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-9342","authenticated-orcid":false,"given":"Reyad","family":"Dada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"issue":"1","key":"3226_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ajh.24226","volume":"91","author":"SM Ansell","year":"2016","unstructured":"Ansell SM (2016) Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. Am J Hematol 91(1):109\u2013112. https:\/\/doi.org\/10.1002\/ajh.24226","journal-title":"Am J Hematol"},{"issue":"9","key":"3226_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","volume":"4","author":"DL Longo","year":"1986","unstructured":"Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr (1986) Twenty years of MOPP therapy for Hodgkin\u2019s disease. J Clin Oncol 4(9):1295\u20131306. https:\/\/doi.org\/10.1200\/jco.1986.4.9.1295","journal-title":"J Clin Oncol"},{"issue":"13","key":"3226_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","volume":"14","author":"A Younes","year":"2013","unstructured":"Younes A, Connors JM, Park SI, Fanale M, O\u2019Meara MM, Hunder NN, Huebner D, Ansell SM (2013) Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 14(13):1348\u20131356. https:\/\/doi.org\/10.1016\/S1470-2045(13)70501-1","journal-title":"Lancet Oncol"},{"issue":"2","key":"3226_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1023\/A:1008294312741","volume":"8","author":"V Diehl","year":"1997","unstructured":"Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin\u2019s disease. The German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol 8(2):143\u2013148. https:\/\/doi.org\/10.1023\/A:1008294312741","journal-title":"Ann Oncol"},{"issue":"6","key":"3226_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14712598.2016.1180362","volume":"16","author":"R Dada","year":"2016","unstructured":"Dada R, Zekri J, Al Saadi R (2016) Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis. Expert Opin Biol Ther 16(6):739\u2013745. https:\/\/doi.org\/10.1080\/14712598.2016.1180362","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"3226_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","volume":"128","author":"A Kumar","year":"2016","unstructured":"Kumar A, Casulo C, Yahalom J, Schoder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH (2016) Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 128(11):1458\u20131464. https:\/\/doi.org\/10.1182\/blood-2016-03-703470","journal-title":"Blood"},{"key":"3226_CR7","doi-asserted-by":"crossref","unstructured":"Rubinstein PG, Moore P, Henry DH, Ratner L, Sharon E, Noy A (2015) AMC-085: a pilot trial of AVD and Brentuximab Vedotin in the upfront treatment of stage II-IV HIV-associated Hodgkin lymphoma. A trial of the AIDS Malignancy Consortium. Blood 126 (23)","DOI":"10.1182\/blood.V126.23.1526.1526"},{"key":"3226_CR8","doi-asserted-by":"publisher","unstructured":"Ansell SM (2016) Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1387","DOI":"10.1158\/1078-0432.CCR-16-1387"},{"issue":"4","key":"3226_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"3226_CR10","doi-asserted-by":"crossref","unstructured":"Timmerman J, Engert A, Younes A, Santoro A, Armand P, Fanale MA, Collins GP, Ratanatharathorn V, Kuruvilla J, Cohen JB, Savage KJ, Trneny M, De Boer JP, Shipp MA, Rodig SJ, Zinzani PL, Kato K, Sumbul A, Ansell A (2016) Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed\/refractory classical hodgkin lymphom. ASH Meeting, abstract 1110","DOI":"10.1182\/blood.V128.22.1110.1110"},{"issue":"9","key":"3226_CR11","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X","journal-title":"Lancet Oncol"},{"key":"3226_CR12","unstructured":"Zinzani PL, Engert A, Younes A, Santoro A, Ansell S, Timmerman J, Collins GP, Armand P, Savage KJ, Trneny M, Fanale M, Kuruvilla J, Cohen JB, Shipp M, Rodig S, Kato K, Sumbul A, Farsaci BA, Ratanatharathorn V (2016) Checkmate 205 Cohort C: Nivolumab in patients with classical Hodgkin lymphoma after brentuximab vedotin and autologous hematopoietic stem cell transplantation. International Hodgkin Lymphoma Symposium (ishl) Abstract, T022"},{"key":"3226_CR13","doi-asserted-by":"publisher","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed Death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2016.67.3467","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"3226_CR14","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, Tresckow B, Shipp MA, Gustafson E, Zhang Y, Ricart AD, Balakumaran A, Chen RW (2016) Pembrolizumab in relapsed\/refractory classical hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 Study. ASH Meeting, abstract 1107","DOI":"10.1182\/blood.V128.22.1107.1107"},{"issue":"18","key":"3226_CR15","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"5","key":"3226_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/cas.13230","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, Ando K, Terui Y, Higuchi Y, Onishi Y, Abe Y, Kobayashi T, Shirasugi Y, Tobinai K (2017) Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci 108(5):1007\u20131012. https:\/\/doi.org\/10.1111\/cas.13230","journal-title":"Cancer Sci"},{"key":"3226_CR17","doi-asserted-by":"crossref","unstructured":"Herrera AF, Bartlett NL, Ramchandren R, Vose JM, Moskowitz AJ, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Kato K, Fong A, Advani RH (2016) Preliminary results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory hodgkin lymphoma. ASH Meeting, abstract 1105","DOI":"10.1182\/blood.V128.22.1105.1105"},{"key":"3226_CR18","doi-asserted-by":"crossref","unstructured":"Diefenbach CS, Hong F, David KA, Cohen J, Robertson M, Advani R, Palmisiano ND, Ambinder RF, Kahl BS, Ansell S A Phase I (2016) Study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory hodgkin lymphoma: a Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). ASH Meeting, abstract 1106","DOI":"10.1182\/blood.V128.22.1106.1106"},{"issue":"17","key":"3226_CR19","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1517\/14656566.2010.515979","volume":"11","author":"B Rathore","year":"2010","unstructured":"Rathore B, Kadin ME (2010) Hodgkin\u2019s lymphoma therapy: past, present, and future. Expert Opin Pharmacother 11(17):2891\u20132906. https:\/\/doi.org\/10.1517\/14656566.2010.515979","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 2","key":"3226_CR20","doi-asserted-by":"publisher","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","volume":"3","author":"TC Gangadhar","year":"2016","unstructured":"Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ, Balmanoukian AS, Kaufman DR, Zhao Y, Maleski J, Leopold L, Gajewski TF (2016) Preliminary results from a phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer 3(Suppl 2):O7","journal-title":"J Immunother Cancer"},{"issue":"7","key":"3226_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP (2013) Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389\u20131402. https:\/\/doi.org\/10.1084\/jem.20130066","journal-title":"J Exp Med"},{"issue":"9","key":"3226_CR22","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. P Natl Acad Sci USA 112(9):E966\u2013E972. https:\/\/doi.org\/10.1073\/pnas.1500712112","journal-title":"P Natl Acad Sci USA"},{"issue":"2","key":"3226_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00066-016-1050-4","volume":"193","author":"C Baues","year":"2016","unstructured":"Baues C, Semrau R, Gaipl US, Brockelmann PJ, Rosenbrock J, Engert A, Marnitz S (2016) Checkpoint inhibitors and radiation treatment in Hodgkin\u2019s lymphoma : new study concepts of the German Hodgkin Study Group. Strahlenther Onkol 193(2):95\u201399. https:\/\/doi.org\/10.1007\/s00066-016-1050-4","journal-title":"Strahlenther Onkol"},{"key":"3226_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fimmu.2015.00505","volume":"6","author":"A Derer","year":"2015","unstructured":"Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US (2015) Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses\u2014pre-clinical evidence and ongoing clinical applications. Front Immunol 6:505. https:\/\/doi.org\/10.3389\/Fimmu.2015.00505","journal-title":"Front Immunol"},{"issue":"2","key":"3226_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.canlet.2015.04.007","volume":"368","author":"GG Hanna","year":"2015","unstructured":"Hanna GG, Coyle VM, Prise KM (2015) Immune modulation in advanced radiotherapies: targeting out-of-field effects. Cancer Lett 368(2):246\u2013251. https:\/\/doi.org\/10.1016\/j.canlet.2015.04.007","journal-title":"Cancer Lett"},{"key":"3226_CR26","doi-asserted-by":"crossref","unstructured":"Engert A, Taylor F, Bennett B, Hirji I, Cocks K, McDonald J, Mann E, Kato K, Cella D (2016) Patient subgroup analysis of quality-of-life outcomes in CheckMate 205, a phase 2 study of nivolumab in patients with classical Hodgkin lymphoma. ASH Meeting, December 2016, abstract 1831","DOI":"10.1182\/blood.V128.22.1831.1831"},{"issue":"18","key":"3226_CR27","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquieres H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471\u20132478. https:\/\/doi.org\/10.1182\/blood-2016-11-749556","journal-title":"Blood"},{"issue":"1","key":"3226_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51(1):25\u201330. https:\/\/doi.org\/10.2967\/jnumed.109.067892","journal-title":"J Nucl Med"},{"issue":"21","key":"3226_CR29","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"issue":"31","key":"3226_CR30","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541\u20133543. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870","journal-title":"J Clin Oncol"},{"issue":"22","key":"3226_CR31","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1158\/1078-0432.CCR-14-3128","volume":"21","author":"A Hoos","year":"2015","unstructured":"Hoos A, Wolchok JD, Humphrey RW, Hodi FS (2015) CCR 20th anniversary commentary: immune-related response criteria\u2014capturing clinical activity in immuno-oncology. Clin Cancer Res 21(22):4989\u20134991. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3128","journal-title":"Clin Cancer Res"},{"key":"3226_CR32","doi-asserted-by":"publisher","unstructured":"Dercle L, Seban RD, Lazarovici J, Schwartz L, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM (2017) 18F-FDG PET and CT-scan detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-PD1 immune checkpoint inhibitor. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.117.193011","DOI":"10.2967\/jnumed.117.193011"},{"key":"3226_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ctrv.2017.01.009","volume":"54","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH (2017) Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 54:99\u2013109. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.009","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"3226_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","volume":"94","author":"S Paydas","year":"2015","unstructured":"Paydas S, Bagir E, Seydaoglu G, Ercolak V, Ergin M (2015) Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 94(9):1545\u20131552. https:\/\/doi.org\/10.1007\/s00277-015-2403-2","journal-title":"Ann Hematol"},{"issue":"14","key":"3226_CR35","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1505857","volume":"373","author":"M Hamadani","year":"2015","unstructured":"Hamadani M, Balasubramanian S, Hari PN (2015) Ibrutinib in refractory classic Hodgkin\u2019s lymphoma. N Engl J Med 373(14):1381\u20131382. https:\/\/doi.org\/10.1056\/NEJMc1505857","journal-title":"N Engl J Med"},{"issue":"19","key":"3226_CR36","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","volume":"118","author":"TA Fehniger","year":"2011","unstructured":"Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118(19):5119\u20135125. https:\/\/doi.org\/10.1182\/blood-2011-07-362475","journal-title":"Blood"},{"issue":"8","key":"3226_CR37","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119(8):1897\u20131900. https:\/\/doi.org\/10.1182\/blood-2011-10-386763","journal-title":"Blood"},{"issue":"7","key":"3226_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2174\/092986712799320727","volume":"19","author":"A Guarini","year":"2012","unstructured":"Guarini A, Minoia C, Giannoccaro M, Rana A, Iacobazzi A, Lapietra A, Raimondi A, Silvestris N, Gadaleta CD, Ranieri G (2012) mTOR as a target of everolimus in refractory\/relapsed Hodgkin lymphoma. Curr Med Chem 19(7):945\u2013954","journal-title":"Curr Med Chem"},{"issue":"12","key":"3226_CR39","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-017-3226-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:33:26Z","timestamp":1659058406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-017-3226-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3226"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3226-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,1,10]]},"assertion":[{"value":"14 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}